Paratek Pharma buy Quitte
Startpreis
02.03.17
/
50%
14,25 €
Kursziel
10.04.17
20,20 €
Rendite (%)
43,35 %
Endpreis
10.04.17
20,43 €
Zusammenfassung
Diese Einschätzung wurde am 10.04.17 mit einem Endkurs von 20,43 € beendet. Satte Gewinne von 43,35 % verzeichnete die BUY Einschätzung von Quitte. Quitte hat 50% Zuversicht bei dieser Einschätzung
Finanztrends
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Paratek Pharma | - | - | - | - |
| iShares Core DAX® | 0.300% | 4.701% | 4.537% | 51.554% |
| iShares Nasdaq 100 | 0.434% | 12.255% | 31.983% | 98.287% |
| iShares Nikkei 225® | 1.633% | 12.616% | 43.258% | 69.873% |
| iShares S&P 500 | 0.566% | 7.786% | 23.475% | 69.791% |
Kommentare von Quitte zu dieser Einschätzung
In der Diskussion Paratek Pharma diskutieren
sieht doch gut aus
Stand 2. März 2017
BOSTON (AP) _ Paratek Pharmaceuticals Inc. (PRTK) on Thursday reported a loss of $26.5 million in its fourth quarter.
The Boston-based company said it had a loss of $1.16 per share.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.29 per share.
The pharmaceutical company posted revenue of $29,000 in the period.
For the year, the company reported that its loss widened to $111.6 million, or $5.51 per share. Revenue was reported as $29,000.
Paratek shares have decreased roughly 2 percent since the beginning of the year. The stock has dropped nearly 3 percent in the last 12 months.
(Zielkurs erreicht)